Rapport Therapeutics officer sells 360 shares

Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares of Common Stock in an open-market transaction at $34.90 per share on April 8, 2026.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares of Common Stock in an open-market transaction at $34.90 per share on April 8, 2026.

After this sale, he directly holds 286,516 shares of Rapport Therapeutics Common Stock. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was pre-arranged.

Insider Trade Summary 10b5-1

Net Seller: 360 shares

Net Sell 1 txn

Insider Yeleswaram Krishnaswamy

Role Chief Development Officer

Sold 360 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	360	$34.90	$13K

Holdings After Transaction: Common Stock — 286,516 shares (Direct)

Footnotes (1)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Key Figures

Shares sold: 360 shares Sale price: $34.90 per share Shares held after transaction: 286,516 shares

3 metrics

Shares sold 360 shares Open-market sale on April 8, 2026

Sale price $34.90 per share Price for Common Stock sale

Shares held after transaction 286,516 shares Direct Common Stock ownership following sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rapport Therapeutics (RAPP) report on this Form 4?

Rapport Therapeutics reported that its Chief Development Officer, Yeleswaram Krishnaswamy, sold 360 shares of Common Stock. The shares were sold in an open-market transaction at $34.90 per share, and the sale was made under a pre-arranged Rule 10b5-1 trading plan.

How many Rapport Therapeutics (RAPP) shares did the insider sell and at what price?

The insider sold 360 shares of Rapport Therapeutics Common Stock at $34.90 per share. This was an open-market sale, meaning the transaction occurred on the public market at prevailing prices on the transaction date.

How many Rapport Therapeutics (RAPP) shares does the insider hold after the sale?

After the reported sale, the Chief Development Officer directly holds 286,516 shares of Rapport Therapeutics Common Stock. This shows that the 360-share transaction represents a very small portion of his overall reported direct holdings in the company.

Was the Rapport Therapeutics (RAPP) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transactions were effected under a Rule 10b5-1 trading plan adopted on December 10, 2025. Such pre-arranged plans schedule trades in advance, helping insiders trade stock without making day-to-day timing decisions.

Who is the insider involved in this Rapport Therapeutics (RAPP) Form 4 filing?

The insider is Yeleswaram Krishnaswamy, who serves as Chief Development Officer at Rapport Therapeutics. He is reported as an officer of the company and holds his reported shares directly rather than through an intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/09/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeleswaram Krishnaswamy

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/08/2026		S(1)		360	D	$34.9	286,516	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

	/s/ Troy Ignelzi, Attorney-in-Fact	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)